Orforglipron

Orforglipron guides

Orforglipron is an oral small-molecule GLP-1 receptor agonist, sold in the United States as Foundayo at US$149 to US$299 a month. It is not approved in Canada: Health Canada has issued no Notice of Compliance, so it is Pre-NOC. Every guide below carries a date and a source.

The drug

• What Is Orforglipron?

  The first GLP-1 that works as an ordinary daily pill, and why that is harder than it sounds.

  Read guide →

• Orforglipron Side Effects

  Trial reporting rates by dose, how many people stopped, the boxed warning and the liver question.

  Read guide →

• Orforglipron Price

  US self-pay pricing dose by dose, and why no honest Canadian price exists yet.

  Read guide →

• Orforglipron Brand Name

  Why the same drug is called Foundayo, and which name to search for Canadian news.

  Read guide →

Foundayo in Canada

• Foundayo in Canada

  Why no Canadian pharmacy can stock it yet, and every step left before one can.

  Read guide →

• Approval Timeline

  From the 2025 trial results to the Canadian reimbursement reviews, step by dated step.

  Read guide →

• How to Get Foundayo

  Import rules, clinical trials and the approved GLP-1s you can ask about today.

  Read guide →

• Foundayo vs Rybelsus

  Orforglipron against oral semaglutide: food rules, A1C, weight and tolerability.

  Read guide →